Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Estrogen breast cancer patients’ levels

In premenopausal women the ovary is the richest source of aromatase and hence estrogen. Aromatase is confined to the granulosa cells and is produced under the influence of gonadotropins (FSH and LH). Despite being a rich source of aromatase, three separate studies have shown that aromatase inhibitors are unable to sufficiently suppress ovarian estrogen production to postmenopausal levels. One explanation for this phenomenon may be a compensatory rise in gonadotrophins which maintains adequate estrogen production, despite the presence of the inhibitor. As such aromatase inhibitors cannot be used in premenopausal breast cancer patients. After menopause, ovarian... [Pg.219]

Anastrozole is a selective nonsteroidal aromatase inhibitor that lowers estrogen levels. The pharmacokinetics of anastrozole demonstrate good absorption, with hepatic metabolism the primary route of elimination and only 10% excreted unchanged by the kidney. The elimination half-life is approximately 50 hours. Anastrozole is used for the adjuvant treatment of postmenopausal women with hormone-positive breast cancer and in breast cancer patients who have had disease progression following tamoxifen. Side effects include hot flashes, arthralgias, osteoporosis/bone fractures, and thrombophlebitis. [Pg.1296]

Geisler, J., Haynes, B., Anker, G., Dowsett, M., and Lonning, P. E. 2002. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized crossover study. J. Clin. Oncol. 20 751-57. [Pg.219]

BIO. Bonomi, P., Gale, M., and von Roenn, J., Anderson, K., Johnson, P., Wolter, J., and Economou, S., Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Semin. Oncol. 15(2), 26-33 (1988). [Pg.218]

Although the positive effects of ERT have been well established, it has been shown that the cell proliferative actions of estrogen can increase the incidence of breast cancer in some patients. In addition, duration of exposure to physiological levels of unopposed estrogens is an established risk factor for breast, uterine, and ovarian cancer. In an effort to attain pharmaceutical agents that oppose the carcinogenic... [Pg.1113]

Hypercalcemia Estrogens may lead to severe hypercalcemia in patients with breast cancer and bone metastases. If this occurs, discontinue the drug and take appropriate measures to reduce the serum calcium level. [Pg.179]

Tamoxifen is a competitive partial agonist inhibitor of estradiol at the estrogen receptor and is extensively used in the palliative treatment of advanced breast cancer in postmenopausal women. It is a nonsteroidal agent (see structure below) that is given orally. Peak plasma levels are reached in a few hours. Tamoxifen has an initial half-life of 7-14 hours in the circulation and is predominantly excreted by the liver. It is used in doses of 10-20 mg twice daily. Hot flushes and nausea and vomiting occur in 25% of patients, and many other minor adverse effects are observed. Studies of patients treated with tamoxifen as adjuvant therapy for early breast cancer have shown a 35% decrease in contralateral breast cancer. However, adjuvant therapy extended beyond 5 years in patients with breast cancer has shown no further improvement in outcome. Toremifene is a structurally similar compound with very similar properties, indications, and toxicities. [Pg.960]


See other pages where Estrogen breast cancer patients’ levels is mentioned: [Pg.1297]    [Pg.1318]    [Pg.126]    [Pg.142]    [Pg.711]    [Pg.104]    [Pg.106]    [Pg.118]    [Pg.270]    [Pg.129]    [Pg.85]    [Pg.115]    [Pg.1453]    [Pg.2444]    [Pg.2355]    [Pg.415]    [Pg.490]    [Pg.785]    [Pg.245]    [Pg.1316]    [Pg.268]    [Pg.330]    [Pg.155]    [Pg.41]    [Pg.58]    [Pg.208]    [Pg.900]    [Pg.902]    [Pg.906]    [Pg.912]    [Pg.940]    [Pg.942]    [Pg.950]    [Pg.316]    [Pg.135]    [Pg.71]    [Pg.433]    [Pg.783]    [Pg.272]    [Pg.2339]    [Pg.2352]    [Pg.297]   
See also in sourсe #XX -- [ Pg.139 , Pg.140 , Pg.141 , Pg.142 ]




SEARCH



Breast Estrogens

Breast cancer level

Breast cancer patients

Levels patient

© 2024 chempedia.info